---
title: dFDA Platform Costs - ROM Estimates
description: Detailed rough order of magnitude (ROM) cost estimates for building and operating the dFDA platform
---

## Costs of Building and Operating the Global Decentralized FDA ROM Estimate

> **Section Summary**
>
> - **Upfront core platform build:** [\$37.5–\$46 million](#upfront-capital-expenditure-initial-build-illustrative-30-months)
> - **Annual core platform operations:** [\$11–\$26.5 million](#annual-operational-costs-illustrative-at-target-scale-of-5m-mau-50tb-ingest-month)
> - **Broader initiative (medium scenario):** [\$228 million upfront, \$21.3 million annual](#scenario-based-rom-estimates-for-broader-initiative-costs)
> - **Best case total initiative:** [~\$4.5M upfront, near \$0 annual](#scenario-based-rom-estimates-for-broader-initiative-costs)
> - **Worst case total initiative:** [~\$2.2B+ upfront, \$271M+ annual](#scenario-based-rom-estimates-for-broader-initiative-costs)
>
> **Key Takeaway:** The core technology platform is achievable for tens of millions, but full global rollout and integration could require hundreds of millions to billions depending on scope and execution. See detailed breakdowns below.

This section provides a **Rough Order of Magnitude (ROM)** cost estimate based on the components outlined in the <!-- [Platform Technical Specification](../specification.qmd) -->.

### Upfront (Capital) Expenditure Initial Build Illustrative 30 Months

1. **Core Engineering & Development Effort:**

   - _Basis:_ ~75 FTEs _2.5 years_ \$200k/FTE/year
   - _Activities:_ Detailed design, core platform development (API, storage, mapping/validation, auth), reference frontend, initial plugin interfaces, testing, documentation, initial deployment.
   - **Estimated ROM:** [\$35 - \$40 Million](#upfront-capital-expenditure-initial-build-illustrative-30-months)

2. **Infrastructure Setup & Initial Cloud Costs:**

   - _Activities:_ Establishing cloud accounts, VPCs, Kubernetes cluster (EKS) setup, database provisioning (RDS/TimescaleDB), S3 buckets, CI/CD pipeline setup, initial IaC development (Terraform).
   - _Costs:_ Includes initial compute/storage during development/testing, potential small upfront reservations.
   - **Estimated ROM:** [\$1 - \$3 Million](#upfront-capital-expenditure-initial-build-illustrative-30-months)

3. **Software Licenses & Tooling (Initial):**

   - _Examples:_ Potential costs for monitoring tools (Datadog), security scanners (Snyk), specialized libraries, collaboration tools if not already covered.
   - **Estimated ROM:** [\$0.5 - \$1 Million](#upfront-capital-expenditure-initial-build-illustrative-30-months)

4. **Compliance, Legal & Security (Initial Setup):**

   - _Activities:_ Initial HIPAA/GDPR compliance assessment, policy development, security architecture review, legal consultation for data sharing frameworks.
   - **Estimated ROM:** [\$1 - \$2 Million](#upfront-capital-expenditure-initial-build-illustrative-30-months)

> **Total Estimated Upfront Cost (ROM): [\$37.5 - \$46 Million](#upfront-capital-expenditure-initial-build-illustrative-30-months)**

_Note: This ROM estimate focuses **only on the Core Platform build effort and associated setup**. It represents the foundational first step. The full vision of the ["Right to Trial and FDA Upgrade Act"](right-to-trial-fda-upgrade-act.qmd) requires significant additional investment in broader initiatives to achieve its goals of global integration, legal harmonization, and massive scale. These crucial, follow-on costs are estimated separately in the [Scenario Based ROM Estimates for Broader Initiative Costs](#scenario-based-rom-estimates-for-broader-initiative-costs) section below and include:_

- _Global EHR/Data Source Integration Effort:_ Building/buying connectors for _thousands_ of systems worldwide.
- _Large-Scale Plugin Development:_ Funding the ecosystem of data importers, analysis tools, and visualization plugins.
- _International Legal/Regulatory Harmonization:_ Major diplomatic and legal efforts to create a global standard.
- _Global Rollout & Adoption:_ Costs associated with driving adoption and providing training worldwide.
- _Massive-Scale Infrastructure:_ Scaling hardware and cloud resources beyond initial targets to support millions of users as mandated by the Act.

The following sections provide ROM estimates for both the ongoing operational costs of the core platform and for these essential broader initiatives.

### Top-Down Analogous Cost Estimation (Market Comparables)

To complement the bottom-up ROM, we can derive a top-down estimate by examining the total investment raised by leading commercial companies developing decentralized clinical trial (DCT) platforms. This market-based view provides a real-world benchmark for the capital required to build, scale, and operate a sophisticated, global-grade platform.

- **Medable:** A leader in the DCT platform space, has raised a total of **[\$521 million](https://hitconsultant.net/2021/10/26/medable-dct-series-d-funding/)** in capital, achieving a valuation of **[\$2.1 billion](https://informaconnect.com/decentralized-trial-tech-firm-medable-raises-another-300m/)** as of late 2021. This level of funding represents the capital required to develop a comprehensive SaaS platform, establish a global presence across 60+ countries, and achieve significant market penetration.
- **Other DCT Platform Companies:** Other companies in the space, such as **[Science 37](https://www.mobihealthnews.com/news/exo-raises-40m-handheld-ultrasound-decentralized-trial-platforms-raise-nearly-100m-and-more)** (~\$40M raised), **[Thread](https://www.mobihealthnews.com/news/exo-raises-40m-handheld-ultrasound-decentralized-trial-platforms-raise-nearly-100m-and-more)** (up to \$50M raised), and **[uMotif](https://www.pharmasalmanac.com/articles/umotif-the-patient-first-data-capture-and-decentralized-clinical-trials-platform-announces-25.5m-of-new-investment-from-a-fund-managed-by-athyrium-capital-management)** (~\$25.5M raised), show that significant traction and platform development can be achieved with investments in the tens of millions.

**Analogous ROM Conclusion:**

Based on these market comparables, the total investment required to fund a global dFDA Infrastructure initiative, from initial build to widespread adoption, can be estimated to be in the range of **\$50 million to \$500 million**.

- The lower end (~\$50M) aligns with the capital needed to build a robust platform and achieve initial scale, similar to companies like Science 37 or Thread.
- The upper end (~\$500M+) reflects the multi-year investment needed to build a market-leading, feature-rich global platform with a vast ecosystem, analogous to the trajectory of Medable.

This top-down estimate corroborates the findings of the bottom-up analysis. While a core, open-source platform can be initiated for tens of millions (as shown in the upfront build ROM), a fully-realized, globally adopted dFDA ecosystem represents a **multi-hundred-million-dollar undertaking**, consistent with the "Medium Case" and "Worst Case" scenarios for broader initiative costs.

### Annual Operational Costs Illustrative at Target Scale of 5M MAU 50TB Ingest Month

1. **Cloud Infrastructure Costs (AWS):**

   - _Components:_ EKS cluster, RDS/TimescaleDB hosting, S3 storage & requests, SQS messaging, API Gateway usage, Data Transfer (egress), CloudWatch logging/monitoring.
   - _Basis:_ Highly dependent on actual usage patterns, data retrieval frequency, processing intensity. Assumes optimized resource usage.
   - **Estimated ROM:** \$5 - \$15 Million / year (Very sensitive to scale and usage patterns)

2. **Ongoing Engineering, Maintenance & Operations:**

   - _Team Size:_ Assume ~20 FTEs (SREs, DevOps, Core Maintainers, Security).
   - _Basis:_ 20 FTEs \* \$200k/FTE/year
   - **Estimated ROM:** \$4 - \$6 Million / year

3. **Software Licenses & Tooling (Ongoing):**

   - _Examples:_ Monitoring (Datadog/New Relic), Error Tracking (Sentry), Security Tools, potential DB license/support costs at scale.
   - **Estimated ROM:** \$0.5 - \$1.5 Million / year

4. **Compliance & Auditing (Ongoing):**

   - _Activities:_ Regular security audits (penetration tests, compliance checks), maintaining certifications, legal reviews.
   - **Estimated ROM:** \$0.5 - \$1 Million / year

5. **Support (User & Developer):**

   - _Activities:_ Tier 1/2 support for platform users and potentially third-party plugin developers.
   - **Estimated ROM:** \$1 - \$3 Million / year (Scales with user base)

> **Total Estimated Annual Operations (Platform Only, ROM): \$11 - \$26.5 Million / year**

#### Marginal Cost Analysis per User

The **5M MAU** target is an illustrative milestone used for these initial ROM estimates, not the ultimate goal for the platform, which aims to support hundreds of millions or billions of users. At this initial scale, we can analyze the cost on a per-user basis.

- **Average Cost Range Per User (at 5M MAU):**
  - Based on the total annual operational cost range of **[\$11M - \$26.5M](#annual-operational-costs-illustrative-at-target-scale-of-5m-mau-50tb-ingest-month)**, the average cost per user is:
    $$
    \frac{\$11,000,000 \text{ to } \$26,500,000}{5,000,000 \text{ users}} = \mathbf{\$2.20 \text{ to } \$5.30 \text{ per user per year}}
    $$

- **Marginal Cost Per Additional User:**
  - As a large-scale software platform, the dFDA system has high fixed costs (infrastructure, core engineering) but very low variable costs. Therefore, the **marginal cost** of supporting one additional user is expected to be a small fraction of the average cost, likely **pennies per year**. This cost will decrease further as the platform achieves greater economies of scale, making the system exceptionally efficient at supporting a global user base.

_(Note: The underlying cloud infrastructure cost (\$5M-\$15M/year) is a top-down ROM estimate. A more granular, bottom-up analysis based on projected per-user storage, data transfer, and compute would provide further support for these figures and is a key area for future refinement of this model.)_

\*Note on Participant Financial Contributions and NIH Cost Discounts (Alignment with "Right to Trial & FDA Upgrade Act"):

This core platform operational cost estimate **focuses on the technology infrastructure and does not include the direct financial transactions related to individual trial participation.** The "Right to Trial & FDA Upgrade Act" (specifically SEC. 303 and SEC. 304) outlines a model where: 1. **Sponsor-Determined Participation Costs:** Sponsors itemize the direct costs of a patient's participation in a trial (SEC. 304(a)). 2. **NIH-Funded Direct Discount:** The NIH Trial Participation Cost Discount Fund directly covers a portion of these patient-borne costs. The specific percentage or amount of this discount is determined by an NIH-managed allocation algorithm aiming to maximize QALYs and other public health benefits (SEC. 303(b, c)). For initial operationalization, while the full algorithm is developed and sufficient data is accrued via the platform, a standardized default discount (e.g., the NIH Fund covering 50% of patient-borne costs) could be applied as a baseline policy. This would allow subsidies to flow quickly, with the mechanism evolving towards the dynamic, data-driven algorithm over time as envisioned in the Act. 3. **Patient Net Cost Contribution:** The patient is responsible for the remaining net cost after the NIH discount is applied (SEC. 304(b)). 4. **Platform Facilitation:** The dFDA Infrastructure's role, as costed in its operational ROM, includes modules (like the Trial Cost and Discount Module per SEC. 204(c)(3)) to transparently display the itemized costs, the NIH-funded discount, and the final net patient contribution. The platform facilitates the management of these financial components but does not itself disburse the NIH funds or determine the discount amounts.

Large-scale figures sometimes discussed for "participant support" or "subsidies" would primarily reflect the total budget and impact of the NIH Trial Participation Cost Discount Fund, not operational outlays by the dFDA Infrastructure for direct compensation (which is not part of this model).

_This estimate also excludes costs associated with running the **DAO governance structure** itself and the cost of developing and maintaining the **plugin ecosystem** (though some plugin development could be incentivized via platform-specific bounties as per the Act)._

### Enhanced ROM Estimates and Cost Optimization

**Disclaimer:** This subsection presents ROM estimates that incorporate the full technical requirements from the "Right to Trial & FDA Upgrade Act" while leveraging cost-saving strategies. The estimates assume successful implementation of open-source development, bounty programs, and AI automation to minimize costs.

**Key Cost-Saving Strategies:**

- **Open-Source Development Model:** Leveraging global developer community contributions under permissive licenses (Apache 2.0/MIT).
- **Bounty & Prize Programs:** Using targeted bounties for specific features, security audits, and integration components.
- **AI-Automated Development:** Utilizing AI coding assistants and automated testing to reduce development time and costs.
- **Modular Architecture:** Enabling parallel development of components by different teams/contributors.
- **Existing Open-Source Components:** Leveraging and contributing back to existing healthcare/blockchain projects.

**ROM Estimates by Technical Component:**

1. **Blockchain Supply-Chain Ledger**

   - Components: Zero-knowledge proof implementation, DSCSA integration, IoT device integration
   - Cost Reduction: Open-source blockchain frameworks, community bounties for core components
   - **Estimated ROM:** [2M USD upfront](#enhanced-rom-estimates-and-cost-optimization) / [0.5M USD annual maintenance](#enhanced-rom-estimates-and-cost-optimization)

2. **Patient Portal & Treatment Ranking System**

- Components: Real-time ranking algorithm, outcome labels, mobile/SMS/IoT interfaces
- Cost Reduction: Open-source frontend frameworks, community-developed plugins
- **Estimated ROM:** [1.5M USD upfront](#enhanced-rom-estimates-and-cost-optimization) / [0.3M USD annual maintenance](#enhanced-rom-estimates-and-cost-optimization)

3. **Interoperability & API Infrastructure**

- Components: FHIR-R5 server, EHR integration adapters, OAuth 2.0 implementation
- Cost Reduction: Existing open-source healthcare APIs, community-contributed adapters
- **Estimated ROM:** [1M USD upfront](#enhanced-rom-estimates-and-cost-optimization) / [0.2M USD annual maintenance](#enhanced-rom-estimates-and-cost-optimization)

4. **Security & Compliance**

- Components: FedRAMP-Moderate compliance, annual pen testing, security monitoring
- Cost Reduction: Bug bounty program, automated security scanning
- **Estimated ROM:** [0.5M USD upfront](#enhanced-rom-estimates-and-cost-optimization) / [0.5M USD annual](#enhanced-rom-estimates-and-cost-optimization)

5. **AI/ML Capabilities**

- Components: Protocol validation, patient-trial matching, safety signal detection
- Cost Reduction: Open-source ML models, transfer learning, community datasets
- **Estimated ROM:** [1M USD upfront](#enhanced-rom-estimates-and-cost-optimization) / [0.3M USD annual](#enhanced-rom-estimates-and-cost-optimization)

6. **Developer & Community Infrastructure**

- Components: Documentation, SDKs, CI/CD pipelines, community support
- Cost Reduction: Automated documentation generation, community moderation
- **Estimated ROM:** [0.5M USD upfront](#enhanced-rom-estimates-and-cost-optimization) / [0.2M USD annual maintenance](#enhanced-rom-estimates-and-cost-optimization)

7. **Governance & Transparency**

- Components: Technical Steering Committee operations, public metrics dashboards
- Cost Reduction: Automated reporting, community governance tools
- **Estimated ROM:** [0.2M USD upfront](#enhanced-rom-estimates-and-cost-optimization) / [0.1M USD annual](#enhanced-rom-estimates-and-cost-optimization)

**Total Estimated Development (Upfront):** [6.7M USD](#enhanced-rom-estimates-and-cost-optimization)
**Total Estimated Annual Operations:** [2.1M USD](#enhanced-rom-estimates-and-cost-optimization)

### Cost Optimization Strategies and Risk Mitigation

**Bounty Program Implementation:**

- [\$1M annual budget](#cost-optimization-strategies-and-risk-mitigation) for security bounties and feature development
- Structured as graduated rewards based on impact and complexity
- Community-voted prioritization of bounty targets

**Open-Source Community Building:**

- Developer documentation and starter kits ([\$0.2M initial](#cost-optimization-strategies-and-risk-mitigation))
- Hackathons and community events ([\$0.3M annual](#cost-optimization-strategies-and-risk-mitigation))
- Contributor recognition program ([\$0.1M annual](#cost-optimization-strategies-and-risk-mitigation))

**AI-Assisted Development:**

- AI code generation and review tools ([\$0.5M initial setup](#cost-optimization-strategies-and-risk-mitigation))
- Automated testing and validation pipelines ([\$0.3M annual](#cost-optimization-strategies-and-risk-mitigation))
- Continuous training of domain-specific models ([\$0.2M annual](#cost-optimization-strategies-and-risk-mitigation))

**Risk Mitigation:**

- 20% contingency buffer on all estimates
- Phased rollout with clear milestones
- Regular third-party security audits

> **Total Estimated ROM with Optimization:**
>
> - **Upfront (Year 1):** [\$8.5M (including contingency)](#cost-optimization-strategies-and-risk-mitigation)
> - **Annual Operations (Years 2+):** [\$3.0M (including bounties and community programs)](#cost-optimization-strategies-and-risk-mitigation)

_Note: These optimized ROM estimates reflect a strategic approach leveraging open-source, community engagement, and AI to deliver the comprehensive dFDA Infrastructure capabilities mandated by the Act in a cost-effective manner. The success of this model hinges on robust community participation and effective management of bounty and prize programs._

### Scenario Based ROM Estimates for Broader Initiative Costs

This table presents point estimates for each scenario, with the overall range of possibilities captured by comparing the Best, Medium, and Worst Case columns.

| Component                                    | Best Case (Upfront / Annual) | Medium Case (Upfront / Annual) | Worst Case (Upfront / Annual) | Key Assumptions & Variables Driving Range                                                                  |
| :------------------------------------------- | :--------------------------- | :----------------------------- | :---------------------------- | :--------------------------------------------------------------------------------------------------------- |
| **Global Data Integration**                  | $2M / ~$0                    | $125M / $10M                   | $1.5B / $150M                 | Success of AI/automation, standards adoption, #systems, vendor cooperation.                                |
| **Bounty & Prize Program (Act SEC. 204(i))** | $1M (Prizes) / ~$0           | $15M (Bounties) / $2M          | $50M (Major Bounties) / $10M  | Success of organic ecosystem growth vs. need to incentivize critical plugin/tool development via bounties. |
| **Legal/Regulatory Harmonization**           | $1.5M / ~$0                  | $60M / $3M                     | $300M / $30M                  | Effectiveness of AI legal tools, political will, complexity of global law.                                 |
| **Global Rollout & Adoption**                | ~$0 / ~$0                    | $12M / $3M                     | $125M / $30M                  | Need for training/support beyond platform status, user interface complexity.                               |
| **DAO Governance Operations**                | ~$0 / ~$0                    | ~$1M / $0.3M                   | ~$6M / $1M                    | Automation level, need for audits, grants, core support staff.                                             |
| **--- TOTAL ---**                            | **~$4.5M / ~$0**             | **~$213M / ~$18.3M**           | **~$1.98B+ / ~$221M+**        | Represents total initiative cost excluding core platform build/ops.                                        |

**Interpretation:**

Even when pursuing efficient strategies, the potential cost for the full dFDA initiative (beyond the core platform) varies dramatically based on real-world execution challenges. The Medium Case suggests upfront costs in the low hundreds of millions and annual costs in the low tens of millions, while the Worst Case pushes towards multi-billion dollar upfront figures and annual costs in the hundreds of millions, dominated by integration, plugin funding, and legal costs if automation and community efforts fall short.

**Revised Summary:**

Based on the detailed technical specification, a ROM estimate suggests:

- **Initial Core Platform Build (~2.5 years): [~\$37.5 - \$46 Million](#upfront-capital-expenditure-initial-build-illustrative-30-months)**
- **Annual Core Platform Operations (at ~5M MAU scale): [~\$11 - \$26.5 Million](#annual-operational-costs-illustrative-at-target-scale-of-5m-mau-50tb-ingest-month)** (These platform operational costs are distinct from the financial flows of patient contributions and the NIH Trial Participation Cost Discount Fund, and also exclude plugin ecosystem costs not covered by platform bounties)

This revised, bottom-up ROM highlights that while the core _technology platform_ build might be achievable within tens of millions, the previously estimated billions likely reflect the total cost of the entire global initiative. This includes massive integration efforts, legal frameworks, global rollout, and the financial ecosystem involving participant contributions and the direct NIH-funded discounts to patient costs, rather than direct platform-disbursed compensation. This conclusion is further supported by the top-down analogous estimate derived from market comparables, which points to a **total initiative investment in the range of \$50 million to \$500 million** for a commercial-grade equivalent.
